Last reviewed · How we verify

Ozurdex Drug Implant Product

Sudhalkar Eye Hospital · FDA-approved active Small molecule

Ozurdex Drug Implant Product is a Corticosteroid implant Small molecule drug developed by Sudhalkar Eye Hospital. It is currently FDA-approved for Macular edema following retinal vein occlusion, Macular edema associated with uveitis, Diabetic macular edema. Also known as: Dexamethasone.

Ozurdex is a sustained-release dexamethasone implant that delivers corticosteroid directly to the posterior segment of the eye to reduce inflammation.

Ozurdex is a sustained-release dexamethasone implant that delivers corticosteroid directly to the posterior segment of the eye to reduce inflammation. Used for Macular edema following retinal vein occlusion, Macular edema associated with uveitis, Diabetic macular edema.

At a glance

Generic nameOzurdex Drug Implant Product
Also known asDexamethasone
SponsorSudhalkar Eye Hospital
Drug classCorticosteroid implant
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

The implant releases dexamethasone, a potent corticosteroid, over an extended period (approximately 3 months) into the vitreous cavity. This localized delivery suppresses inflammatory cytokines and reduces macular edema and inflammation associated with various retinal conditions. The sustained-release formulation allows for prolonged therapeutic effect with a single intravitreal injection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ozurdex Drug Implant Product

What is Ozurdex Drug Implant Product?

Ozurdex Drug Implant Product is a Corticosteroid implant drug developed by Sudhalkar Eye Hospital, indicated for Macular edema following retinal vein occlusion, Macular edema associated with uveitis, Diabetic macular edema.

How does Ozurdex Drug Implant Product work?

Ozurdex is a sustained-release dexamethasone implant that delivers corticosteroid directly to the posterior segment of the eye to reduce inflammation.

What is Ozurdex Drug Implant Product used for?

Ozurdex Drug Implant Product is indicated for Macular edema following retinal vein occlusion, Macular edema associated with uveitis, Diabetic macular edema.

Who makes Ozurdex Drug Implant Product?

Ozurdex Drug Implant Product is developed and marketed by Sudhalkar Eye Hospital (see full Sudhalkar Eye Hospital pipeline at /company/sudhalkar-eye-hospital).

Is Ozurdex Drug Implant Product also known as anything else?

Ozurdex Drug Implant Product is also known as Dexamethasone.

What drug class is Ozurdex Drug Implant Product in?

Ozurdex Drug Implant Product belongs to the Corticosteroid implant class. See all Corticosteroid implant drugs at /class/corticosteroid-implant.

What development phase is Ozurdex Drug Implant Product in?

Ozurdex Drug Implant Product is FDA-approved (marketed).

What are the side effects of Ozurdex Drug Implant Product?

Common side effects of Ozurdex Drug Implant Product include Cataract progression, Elevated intraocular pressure, Conjunctival hemorrhage, Floaters, Eye pain.

What does Ozurdex Drug Implant Product target?

Ozurdex Drug Implant Product targets Glucocorticoid receptor and is a Corticosteroid implant.

Related